Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7204577 | 0.83 | MTNR1A (0.51) | MTNR1ASCN1ASCN2ASCN3AAHR | |
| SCHEMBL7198607 | 0.80 | MTNR1A (0.53) | MTNR1ASCN1ASCN2ASCN3AALOX5 | |
| SCHEMBL6555327 | 0.80 | MTNR1A (0.57) | MTNR1ASCN1ASCN2ASCN3AALOX5 | |
| SCHEMBL7203987 | 0.80 | MTNR1A (0.53) | MTNR1ASCN1ASCN2ASCN3AALOX5 | |
| SCHEMBL17002620 | 0.77 | MTNR1A (0.53) | MTNR1ASCN1ASCN2ASCN3AAHR | |
| SCHEMBL7203114 | 0.75 | MTNR1A (0.47) | MTNR1ASCN1ASCN2ASCN3AAHR | |
| SCHEMBL7203743 | 0.73 | MTNR1A (1.00) | MTNR1ASCN1ASCN2ASCN3A | |
| SCHEMBL7203724 | 0.70 | MTNR1A (0.72) | MTNR1ASCN1ASCN2ASCN3A | |
| SCHEMBL7199016 | 0.70 | MTNR1A (0.64) | MTNR1ASCN1ASCN2ASCN3ATDP1 | |
| SCHEMBL10862979 | 0.70 | MTNR1A (0.50) | MTNR1ASCN1ASCN2ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602903-B2 | Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. | LES LABORATORIES SERVIER (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020052400-A1 | Substituted heterocyclic compounds | ADIR ET COMPAGNIE | 2002-05-02 | — | — | US | disclosed |
| US-6313160-B1 | FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-06 | — | — | US | disclosed |
| EP-0998471-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME | ADIR ET COMPAGNIE (FR) | 2000-05-10 | — | — | EP | disclosed |
| WO-1998052935-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME | ADIR ET COMPAGNIE (FR) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052400-A1 | Substituted heterocyclic compounds | MTNR1A, MTNR1B, CBR1 | MTNR1A 1/4885SCN1A 1081/4885SCN2A 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.